Clinical trials: SARS-CoV-2 Infection
COVID-19 Drug Treatment
A Study to Learn About the Patients With COVID-19 Prescribed Paxlovid in Morocco
The purpose of this study is to collect information on the: general information of a group of people such as their age, sex, and other facts. clinical information of the patients such as any other illness before having COVID 19.
- Trial name
- NCT05997485
- Testing
- Nirmatrelvir/Ritonavir
- Sponsor
- Pfizer
SARS-CoV-2 Infection, COVID-19
Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children
This is a Phase 1/2/3 study in healthy children. Dependent upon safety and/or immunogenicity data generated during the course of this study, and the resulting assessment of benefit-risk, the safety, tolerability, and…
- Trial name
- NCT04816643
- Testing
- Biological/Vaccine: BNT162b2 10mcg, BNT162b2 20mcg, BNT162b2 30mcg
- Where
- 128 sites in United States, Brazil and 4 more
- Volunteers
- 11,837 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
Respiratory Distress Syndrome, Adult
COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111
To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of subjects that are alive without respiratory failure at Day 22.
- Trial name
- NCT04388826
- Testing
- Veru-111
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Veru Inc.
COVID-19
Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19)
This study is a randomized, double-blinded, and placebo controlled phase Ⅰ/Ⅱ clinical trial of the SARS-CoV-2 inactivated vaccine manufactured by Sinovac Research \& Development Co., Ltd.
- Trial name
- NCT04352608
- Testing
- Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule, Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule, Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
- Where
- China
- Volunteers
- 744 people, healthy volunteers welcome
- Sponsor
- Sinovac Research and Development Co., Ltd.
COVID-19
CORONA Germany- Clinical Outcome and Risk in Hospitalized COVID-19 Patients - An Epidemiological Study From Germany
This is a multicenter, observational, prospective, epidemiological cohort study at 45 hospitals in Germany, all part of a German hospital network. All hospitalized patients tested positive for SARS-CoV-2 will be included.
- Trial name
- CORONA Germany (NCT04659187)
- Where
- 8 sites in Germany
- Volunteers
- 4,000 people
- Sponsor
- Asklepios proresearch
Acute Respiratory Distress Syndrome
Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19
Recent COVID 19 pandemic has overwhelmed health services all around the world, and humanity has yet to find a cure or a vaccine for the treatment of patients, mainly the severe ones, who pose a therapeutic challenge to healthcare…
- Trial name
- NCT04390152
- Testing
- Wharton's jelly derived Mesenchymal stem cells.
- Where
- 2 sites in Colombia
- Volunteers
- 6 people
- Sponsor
- BioXcellerator
COVID-19
Heterologous Booster Study of COVID-19 Protein Subunit Recombinant Vaccine in Children 12-17 Years of Age
The goal of this clinical trial is to evaluate immune response and safety of SARS-CoV-2 subunit protein recombinant vaccine (IndoVac) as a heterologous booster dose in healthy children 12-17 years of age.
- Trial name
- NCT05727215
- Testing
- SARS-CoV-2 subunit protein recombinant vaccine
- Where
- Indonesia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
COVID-19 Infection, COVID-19 Vaccine Adverse Reaction
Evaluation of Safety and Immunogenicity of a SARS-CoV-2(Severe Acute Respiratory Syndrome Coronavirus 2) Booster Vaccine (LEM-mR203)
A dose-escalation, double-blinded, randomized, placebo-controlled phase 1 study to assess the safety, reactogenicity, and immunogenicity of a SARS-CoV-2 Booster Vaccine (LEM-mR203) in healthy adults aged at 19 to 55 years
- Trial name
- NCT06032000
- Testing
- LEM-mR203
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Lemonex
Long COVID, Post-COVID Syndrome
Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome
REGENECYTE (HPC, Cord Blood, hUCB) for treatment in patients with post-COVID.
- Conditions
- Long COVID, Post-COVID Syndrome, Post COVID-19 Condition
- Trial name
- NCT05682560
- Testing
- REGENECYTE
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- StemCyte, Inc.
Severe COVID-19
Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients
Efficacy and Safety of DWJ1248 with Remdesivir in Severe COVID-19 Patients
- Trial name
- NCT04713176
- Testing
- DWJ1248 with Remdesivir
- Where
- South Korea
- Volunteers
- 240 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
SARS-CoV-2
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
This study will evaluate 2 dose levels of mRNA-1283 in participants ≥6 months to <12 years to determine the optimal dose level per age group.
- Trial name
- NCT07808697
- Testing
- mRNA-1283, mRNA-1273
- Where
- 31 sites in United States, Argentina and 4 more
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19, COVID-19 Acute Respiratory Distress Syndrome
Study of Cysteamine-pantetheine Disulfide (TTI-0102) in Mild to Moderate COVID-19
This is multi-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacodynamics (PD) and efficacy of TTI-0102 for the treatment of patients with mild to moderate COVID-19.
- Trial name
- NCT05212662
- Testing
- TTI-0102
- Sponsor
- Thiogenesis Therapeutics, Inc.
COVID-19 Pneumonia
The Development of a COVID19 Oral Vaccine Consisting of Bacillus Subtilis Spores
This is a study trial to assess the effectiveness of the immune response stimulated by the genetically engineered Bacillus subtilis which express and display Spike protein of the SARS-COV2 on the spore coat.
- Trial name
- NCT05057923
- Testing
- Bacillus subtilis
- Where
- Hong Kong
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- DreamTec Research Limited
Healthy
Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]-PF-07304814 in Healthy Participants
This open-label, single dose study in approximately 5 healthy male and female (of non childbearing potential only) participants has been designed to characterize mass balance and further the understanding of human…
- Trial name
- NCT05050682
- Testing
- PF-07304814
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Pfizer
SARS-CoV-2 Infection, Influenza A
Clinical Validation of an At-Home Flu A/B and COVID-19 Rapid Test
The study's primary objective is to evaluate the performance of the CorDx Tyfast Flu A/B \& COVID-19 At-Home Test for detecting SARS-CoV-2, Influenza A, and B in nasal samples collected by lay users, compared to 510(k)-cleared…
- Conditions
- SARS-CoV-2 Infection, Influenza A, Influenza B
- Trial name
- NCT07430410
- Testing
- CorDx Tyfast Flu A/B & COVID-19 At-Home Multiplex Rapid Test
- Volunteers
- 200 people
- Sponsor
- CorDx, Inc.
Covid19
Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19)
Background - A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first identified in December 2019 as the cause of a respiratory illness COVID-19 in Wuhan City, China.
- Trial name
- NCT04596839
- Testing
- Remdesivir, Standard of Care
- Where
- Bangladesh
- Volunteers
- 60 people
- Sponsor
- Dr. Md. Alimur Reza
SARS-CoV-2
Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection
SNG001 is an inhaled drug that contains a antiviral protein called interferon beta (IFN-β). IFN-β in produced in the lungs during viral lung infections.
- Trial name
- NCT04385095
- Testing
- SNG001
- Where
- 13 sites in United Kingdom
- Volunteers
- 221 people
- Sponsor
- Synairgen Research Ltd.
COVID-19
Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients
The primary objective of this study is to evaluate the time to confirmed clinical recovery in participants hospitalized with COVID-19.
- Trial name
- COMMUNITY (NCT04590586)
- Testing
- Standard of care, Apremilast, Lanadelumab
- Where
- 59 sites in United States, Argentina and 6 more
- Volunteers
- 515 people
- Sponsor
- Amgen
Novel COVID-19-Infected Pneumonia
An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia
This study adopts a randomized, double-blind, placebo parallel control design, and is expected to include 120 eligible patients with severe novel coronavirus pneumonia.
- Trial name
- NCT05686629
- Testing
- Jaktinib hydrochloride tablets
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
COVID-19
Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults
A randomized, observer-blind, placebo-controlled immuno-bridging, and broadening study to demonstrate the equivalence of the immune response between participants enrolled in Phase 3 efficacy trial in India and demographically…
- Trial name
- NCT05258669
- Testing
- BBV152
- Where
- 10 sites in United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Ocugen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.